The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Hepatotoxicity of immune checkpoint inhibitors: a histology study of seven cases in comparison with autoimmune hepatitis and idiosyncratic drug-induced liver injury
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
ChILI shows less severe confluent necrosis and plasma cell infiltration, fewer CD4+ and more CD8+ infiltrating lymphocytes than classical AIH on liver biopsies.
“ChILI shows less severe confluent necrosis and plasma cell infiltration, fewer CD4+ and more CD8+ infiltrating lymphocytes than classical AIH on liver biopsies.”
From Nomenclature, diagnosis and management of drug-induced autoimmune-like hepatitis (DI-ALH): An expert opinion meeting report (2023) · cites this paper as [42]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945 · cited 2×
“Nivolumab and ipilimumab are now the two most commonly used checkpoint inhibitors [2, 9, 10].”
BackgroundNivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
Motzer, R. J., Escudier, B., McDermott, D. F., George, S., Hammers, H. J., Srinivas, S., Tykodi, S. S., Sosman, J. A., Procopio, G., Plimack, E. R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1510665 · Cited by 5,807
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412082 · Cited by 5,519
Nivolumab plus Ipilimumab in Advanced Melanoma
Wolchok, J. D., Kluger, H., Callahan, M. K., Postow, M. A., Rizvi, N. A., Lesokhin, A. M., Segal, N. H., Ariyan, C. E., Gordon, R.-A., Reed, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302369 · Cited by 4,230 · cited 1×
“Nivolumab and ipilimumab are now the two most commonly used checkpoint inhibitors [2, 9, 10].”
BackgroundManagement of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab
Weber, J. S., Kähler, K. C., & Hauschild, A. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.41.6750 · Cited by 1,415 · cited 1×
“Therefore, the side effects of checkpoint inhibitors are often referred to as “immune-mediated adverse events” in order to distinguish them from usual idiosyncratic drug-induced organ damage [16].”
BackgroundPeggs, K. S., Quezada, S. A., Chambers, C. A., Korman, A. J., & Allison, J. P. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20082492 · Cited by 967
Quezada, S. A., Simpson, T. R., Peggs, K. S., Merghoub, T., Vider, J., Fan, X., Blasberg, R., Yagita, H., Muranski, P., Antony, P. A., et al. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20091918 · Cited by 898
Flagged first, then by citations
Research works printed but not linked: 20
- Postow, 2015, Immune, J Clin Oncol, 33, 1974, 10.1200/JCO.2014.59.4358 · DOI
- Melosky, 2016, Pointed progress in second-line advanced non-small-cell lung cancer: The rapidly evolving field of checkpoint inhibition, J Clin Oncol, 34, 1676, 10.1200/JCO.2015.63.8049 · DOI
- Motzer, 2015, Nivolumab for metastatic renal cell carcinoma: Results of a randomized phase ii trial, J Clin Oncol, 33, 1430, 10.1200/JCO.2014.59.0703 · DOI
- Fong, 2008, Anti-cytotoxic T-lymphocyte antigen-4 antibody: the first in an emerging class of immunomodulatory antibodies for cancer treatment, J Clin Oncol, 26, 5275, 10.1200/JCO.2008.17.8954 · DOI
- Melero, 2007, Immunostimulatory monoclonal antibodies for cancer therapy, Nat Rev Cancer, 7, 95, 10.1038/nrc2051 · DOI
- O'Day, 2007, Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4): a novel strategy for the treatment of melanoma and other malignancies, Cancer, 110, 2614, 10.1002/cncr.23086 · DOI
- Francisco, 2009, PD-L1 regulates the development, maintenance, and function of induced regulatory T cells, J Exp Med, 206, 3015, 10.1084/jem.20090847 · DOI
- Abdel-Wahab, 2016, Adverse events associated with immune checkpoint blockade in patients with cancer: A systematic review of case reports, PLoS ONE, 11, e0160221, 10.1371/journal.pone.0160221 · DOI
- Kim, 2013, Ipilimumab associated hepatitis: imaging and clinicopathologic findings, Invest New Drugs, 31, 1071, 10.1007/s10637-013-9939-6 · DOI
- Johncilla, 2015, Ipilimumab-associated Hepatitis: Clinicopathologic characterization in a series of 11 cases, Am J Surg Pathol, 39, 1075, 10.1097/PAS.0000000000000453 · DOI
- Kleiner, 2012, Pathologic changes in ipilimumab-related hepatitis in patients with metastatic melanoma, Dig Dis Sci, 57, 2233, 10.1007/s10620-012-2140-5 · DOI
- Hennes, 2008, Simplified criteria for the diagnosis of autoimmune hepatitis, Hepatology, 48, 169, 10.1002/hep.22322 · DOI · Paper page
- Ishak, 1995, Histological grading and staging of chronic hepatitis, J Hepatol, 22, 696, 10.1016/0168-8278(95)80226-6 · DOI
- Simonelli, 2016, Pathological characterization of nivolumab-related liver injury in a patient with glioblastoma, Immunotherapy, 8, 1363, 10.2217/imt-2016-0057 · DOI
- Huffman, 2018, Hepatotoxicity After Immune Checkpoint Inhibitor Therapy in Melanoma, American Journal of Clinical Oncology, 41, 760, 10.1097/COC.0000000000000374 · DOI · Paper page
- Lindros, 1997, Zonation of cytochrome P450 expression, drug metabolism and toxicity in liver, Gen Pharmacol, 28, 191, 10.1016/S0306-3623(96)00183-8 · DOI
- Oinonen, 1998, Zonation of hepatic cytochrome P-450 expression and regulation, Biochem J, 329, 17, 10.1042/bj3290017 · DOI
- Gelsomino, 2017, A case of nivolumab-related cholangitis and literature review: how to look for the right tools for a correct diagnosis of this rare immune-related adverse event, Investigational New Drugs, 36, 144, 10.1007/s10637-017-0484-6 · DOI
- Kawakami, 2017, Imaging and clinicopathological features of nivolumab-related cholangitis in patients with non-small cell lung cancer, Invest New Drugs, 35, 529, 10.1007/s10637-017-0453-0 · DOI
- Everett, 2017, Fibrin ring granulomas in checkpoint inhibitor-induced hepatitis, Am J Surg Pathol, 41, 134, 10.1097/PAS.0000000000000759 · DOI
Cited by
Sorted by citations
Andrade, R. J., Aithal, G. P., de Boer, Y. S., Liberal, R., Gerbes, A., Regev, A., Terziroli Beretta-Piccoli, B., Schramm, C., Kleiner, D. E., De Martin, E., et al. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.04.033 · Cited by 166
Self-citationImmune-mediated drug-induced liver injury: immunogenetics and experimental models
Gerussi, A., Natalini, A., Antonangeli, F., Mancuso, C., Agostinetto, E., Barisani, D., Di Rosa, F., Andrade, R., & Invernizzi, P. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094557 · Cited by 87
Biologic and checkpoint inhibitor‐induced liver injury: a systematic literature review
Shah, P., Sundaram, V., & Björnsson, E. (2020) · Hepatology Communications · doi:10.1002/hep4.1465 · Cited by 64
T cells and monocyte-derived myeloid cells mediate immunotherapy-related hepatitis in a mouse model
Llewellyn, H. P., Arat, S., Gao, J., Wen, J., Xia, S., Kalabat, D., Oziolor, E., Virgen-Slane, R., Affolter, T., & Ji, C. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.06.037 · Cited by 47
Metadata
- Authors
- Zen, Y., & Yeh, M. M.
- Venue
- Modern Pathology
- Publisher
- Elsevier BV
- Published
- 2018-06
- Volume
- 31
- Issue
- 6
- Pages
- 965-973
- ISSN
- 0893-3952
- Cited by
- 266
- References
- 9
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
